Refine by
Myeloma Articles & Analysis
15 articles found
The BCL2 gene, short for B-cell lymphoma 2, is a critical regulator of apoptosis, or programmed cell death. It belongs to a larger BCL2 gene family, which includes both pro-apoptotic and anti-apoptotic proteins that maintain a delicate balance between cell survival and cell death. Dysregulation of this gene family is implicated in a variety of diseases, most notably cancer. What is BCL2? The ...
The development of monoclonal antibodies (mAbs) has completely transformed the field of medicine, providing targeted antidotes against a wide range of diseases, including cancer, autoimmune and infectious diseases. These therapeutic antibodies aim to specifically target antigens on the surface of cells and bind to them, leading to acidic reactions that result in the destruction of target cells. ...
Fc fusion protein (Fc-Fusion) has a complex and diverse molecular structure, and may contain glycosylation modification sites at amino acid 297 of its Fc fragment and the Fab region of some molecules. Moreover, its biological ligands are structurally diverse, and their glycosylation modifications may also be complex, usually involving multiple N-glycan and O-glycan sites and a large number of ...
Relationship Between Immunity, Inflammation and Cancer Immunity is an act of self-protection of the body. The immune response is divided into specific and non-specific. The antigen and antibody responses are generally referred to as specific immune responses, which require the participation of B cells and T cells. Other immune cells such as macrophages and NK cells mediate non-specific immune ...
Carfilzomib, a proteasome inhibitor, is indicated for the treatment of patients with multiple myeloma. Multiple myeloma (multiple myeloma, MM) is a malignant tumor originating from the B cell lineage, characterized by the clonal proliferation of malignant plasma cells in the bone marrow microenvironment, causing fractures and bone marrow failure, and is the second most common blood system ...
As September and Blood Cancer Awareness Month wrap up, we want to reflect on a memorable conversation with Karen Thomas, a woman who received clonoSEQ® testing, and her physician, Dr. Hazma Hashmi, a hematologist-oncologist from the Medical University of South Carolina. At Adaptive, we know our diagnostic tests provide key information that help physicians and patients make treatment ...
The day a person receives a cancer diagnosis is likely one of the worst days of their lives. For some new patients, the typical approach may be to seek care from a specialist at an NCCN-designated cancer center. But for the majority of Americans, it will be a community oncologist who guides them through their cancer journey. That’s why Adaptive recently partnered as a sponsor with ...
This September marks four years since the 2018 Food and Drug Administration clearance for clonoSEQ to detect and monitor minimal residual disease (MRD) in bone marrow from patients with acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). In the years following, researchers have explored the value of using MRD status to guide treatment in blood cancers – and the mounting ...
Researchers at Massachusetts General Hospital (MGH) have found that interferon gamma receptor (IFNgR) signaling is essential for the susceptibility of CAR-T cell immunotherapy to kill malignant gliomas. The same phenomenon has been observed in other solid tumors. The findings may partially explain why liquid and solid tumors respond very differently to CAR-T cell therapy. Chimeric antigen ...
In recent years, targeted protein degraders have entered the mainstream of drug development at a very rapid rate. Thalidomide and its derivatives for the treatment of multiple myeloma and other conditions have demonstrated the potential of protein degraders, while ARV-471, an estrogen receptor degrader based on the drug development of thalidomide, is targeted at the early stage of breast cancer ...
Just days before the sunset of the CMS Oncology Care Model, CMS announced its new Enhancing Oncology Model (EOM), the new value-based care oncology payment model. Rolled out as part of the Biden-Harris Administration’s Cancer Moonshot, the goal of EOM is to improve the experience of cancer patients, while advancing health equity and increasing access to care, as well as reducing Medicare ...
At present, chimeric antigen receptor T cell therapy (CAR-T) has made significant achievements in the treatment of specific hematological cancers, allowing patients with relapsed/refractory disease to survive longer and become healthier, but in clinical studies, cell therapy has actually not been successful in the treatment of patients with solid tumors, in part due to the lack of tumor targets ...
Multiple myeloma is an essentially incurable plasma cell cancer with a very poor prognosis for patients; however, in a recent study published in Science Translational Medicine entitled "Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the protein CD98 heavy chain," scientists from Osaka University in Japan have discovered the CD98 heavy chain, a common ...
Increased risk of different cancer types in workers employed in petroleum industries and residents living in oil producing communities by Felix Onyije, Bayan Hosseini, Kayo Togawa, Joachim Schüz, and Ann Olsson Considerable health conditions are caused by environmental pollutants, including emissions from petroleum extraction and refining. They are major sources of environmental and ...
As a kind of enzymes for diagnostic use. Serum amylase (AMS) is the main type of amylase in serum. It belongs to glycoside chain hydrolase, which is mainly derived from the pancreas. In addition, there are also a small amount of secretion in the proximal duodenum, lung, uterus, and breast during lactation. Amylase plays an important role in the digestion of polysaccharide compounds in food. The ...